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CD4 T cell activation leads to proliferation and differ-
entiation into effector (Teff) or regulatory (Treg) cells
that mediate or control immunity. While each subset
prefers distinct glycolytic or oxidative metabolic pro-
grams in vitro, requirements and mechanisms that
control T cell glucose uptake and metabolism in vivo
are uncertain. Despite expression ofmultiple glucose
transporters, Glut1 deficiency selectively impaired
metabolism and function of thymocytes and Teff.
Resting T cells were normal until activated, when
Glut1 deficiencyprevented increasedglucose uptake
and glycolysis, growth, proliferation, and decreased
Teff survival and differentiation. Importantly, Glut1
deficiency decreased Teff expansion and the ability
to induce inflammatory disease in vivo. Treg cells,
in contrast, were enriched in vivo and appeared
functionally unaffected and able to suppress Teff,
irrespective of Glut1 expression. These data show a
selective in vivo requirement for Glut1 in metabolic
reprogramming of CD4 T cell activation and Teff
expansion and survival.
INTRODUCTION
T cell activation initiates a transition from quiescence to rapid cell
growth, proliferation, anddifferentiation into functional subsets to
driveor suppress the immune response (Zhuet al., 2010). Effector
CD4 T cells (Teff; including T helper 1 [Th1], Th2, and Th17) pro-
mote immunity and are enriched in inflammatory diseases. Reg-
ulatory CD4 T cells (Treg), in contrast, suppress immunity and are
decreased in number or function in these settings (Zhu et al.,
2010). Importantly, the transition from quiescence to rapid
growth and proliferation increases energetic and biosynthetic
demands. Activated T cells thus upregulate nutrient uptake andmetabolic rates (MacIver et al., 2013), resulting in a significant
elevation of glucose and amino acid transport (Frauwirth et al.,
2002; Sinclair et al., 2013; Wang et al., 2011) that may modulate
immunity. T cell metabolism has been shown in distinct settings
to require lipid synthesis (Kidani et al., 2013) or oxidation (Bye-
rsdorfer et al., 2013; Gatza et al., 2011), mitochondrial reactive
oxygen species (ROS) (Sena et al., 2013), and amino acid uptake
(Sinclair et al., 2013). However, the in vivo mechanism and roles
of increased glucose uptake and metabolism in T cell-mediated
inflammatory diseases remain uncertain.
It is now evident that metabolic reprogramming is shaped
to support specific cell functions (MacIver et al., 2013). In vitro-
generated Teff strongly induce glycolysis and decrease lipid
oxidation (Michalek et al., 2011a; Shi et al., 2011; Wang et al.,
2011). In contrast, in vitro-induced Treg and memory CD8
T cells utilize lipid oxidation as a primary metabolic pathway
(Michalek et al., 2011a;Pearce et al., 2009;Shi et al., 2011). These
metabolic programs provide distinct metabolites (MacIver et al.,
2013), signaling through the mammalian target of rapamycin
complex 1 (mTORC1) pathway (Sinclair et al., 2013), and cytokine
production (Cham and Gajewski, 2005; Chang et al., 2013).
Importantly, induced Teff and Tregmay be differentially sensitive
to glycolytic inhibition, as in vitro glucose limitation or 2-deoxy-
glucose (2DG) treatment suppressed Th17, but not Treg cells
(Michalek et al., 2011a; Shi et al., 2011). Because these pharma-
cologic approaches result in broad nonspecific effects that
impact all cells, mechanistic insight has been limited. A genetic
approach is needed to establish the cell-intrinsic roles of glucose
metabolism in T cell activation and regulation of inflammation.
Glucose uptake provides a key metabolic control point
through the Glut family of facilitative glucose transporters. The
14 Glut family members are differentially regulated and possess
distinct substrates and biological properties (Thorens and
Mueckler, 2010). The array of Glut transporters utilized by
T cells in activation and differentiation has not yet been defined.
In vitro-stimulated murine and human T cells express high levels
of Glut1 (Slc2a1) (Frauwirth et al., 2002; Jacobs et al., 2008), and
Teff cells maintain levels of Glut1 higher than those of Treg
(Michalek et al., 2011a). Glut1 can promote Teff, as transgenicCell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc. 61
Figure 1. Glut1 Is Selectively and Rapidly Increased in Activated Murine T Cell Activation
(A and B) Glut family mRNA copy number in (A) naive and CD3/CD28-stimulated CD4 murine T cells and (B) in vitro-polarized CD4 T cell subsets. N.D., not
detected.
(C and D) Glut1myc expression in CD3/CD28-stimulated CD4Glut1myc T cells (C) over time and (D) with inhibitors or vehicle control. Mean ± SD from three or more
independent experiments are shown.
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Glut1 Is Required Selectively in CD4 T CellsGlut1 overexpression selectively increased Teff frequency
and led to inflammatory disease (Jacobs et al., 2008; Michalek
et al., 2011a).
Here, we examine the Glut transporter family to directly test
the role and mechanisms that control T cell glucose uptake
and metabolism in activation and in inflammatory disease.
Although T cells expressed four distinct glucose transporter iso-
forms, genetic targeting showed a selective role for Glut1 in pro-
liferative thymocytes and Teff cells. While resting murine and
human T cells were independent of Glut1, Teff required Glut1
for efficient expansion and specification in vivo. In contrast,
both natural and induced Treg were independent of Glut1. As a
result, Glut1-deficient Teff cells were unable to effectively induce
either Graft versus host disease (GvHD) or colitis, while Treg
appeared suppressive independent of Glut1. Thus, Glut1 has a
selective cell-intrinsic function in T cell metabolic reprogram-
ming to drive glycolysis of Teff for growth, expansion, and inflam-
matory disease.
RESULTS
T Cells Express a Subset of Dynamically Regulated Glut
Family Transporters
The mechanism of glucose uptake and role of Glut family
glucose transporters in activation-induced glucose uptake in
T cells has not been directly established. The absolute expres-
sion of each Glut family member was therefore examined.
mRNA transcript copy number was quantified in resting and acti-62 Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc.vated murine T cells (Figure 1A). Of the 13 glucose transporter
family members measured, only Gluts 1, 3, 6, and 8 were de-
tected. Slc2a1 (Glut1) and Slc2a3 (Glut3) mRNA were equally
expressed in resting CD4 T cells. Following activation, Slc2a1
(Glut1) was induced or sustained, while Slc2a3 (Glut3) mRNA
became less prominent. Slc2a6 (Glut6) was also induced with
activation, but remained at a lower copy number than Slc2a1
(Glut1). Glut family member expression was also measured
in induced Th1, Th2, Th17, and Treg (Figure 1B). Again, Gluts
1, 3, 6, and 8 were the only detectable Glut transporters, and
while each T cell subset had a distinct transporter profile, Glut1
was found in the highest copy number in each case. Notably,
differentiated cells expressed Glut3 more similarly to Glut1.
In addition to mRNA levels, the trafficking of Glut1 to the cell
surface is also highly regulated (McCracken and Edinger, 2013;
Wieman et al., 2007). Glut1 protein levels and trafficking were
therefore examined during T cell activation. Because available
antibodies react poorly with the extracellular domains of Glut1,
Glut1myc knockin mice were used to measure cell-surface
Glut1 in T cell development and activation. In this model, a tan-
dem-Myc tagwas knocked into exon 3 ofSlc2a1, which encodes
the large exofacial loop of Glut1, enabling sensitive and specific
flow cytometric measurement of endogenous cell-surface Glut1
using antibodies against the Myc epitope (Michalek et al.,
2011a).
Increased total intracellular expression of Glut1myc was
detected within 2 hr of CD3 and CD28 stimulation. Cell-surface
levels of Glut1myc increased more slowly, but elevated Glut1myc
Figure 2. Glut1 Is Not Required for Survival
of Quiescent Peripheral T Cells
(A and B) Glut1fl/fl and LckCreGlut1fl/fl or
CD4CreGlut1fl/fl T cells were rested in IL-7 (naive)
or CD3/CD28-stimulated for 16 hr, and Glut1
levels were measured by (A) quantitative RT-PCR
(qRT-PCR) or (B) immunoblot.
(C) Flow cytometry is shown for CD4 andCD8 cells
from spleen and inguinal lymph nodes of control
and LckCreGlut1fl/fl mice.
(D) Cell numbers are shown for CD4 and CD8 cells
from spleen and inguinal lymph nodes of control
and LckCreGlut1fl/fl mice.
(E) Flow cytometry is shown for CD4 and CD8 cells
from spleen and inguinal lymph nodes of control
and CD4CreGlut1fl/fl mice.
(F) Cell numbers are shown for CD4 and CD8 cells
from spleen and inguinal lymph nodes of control
and CD4CreGlut1fl/fl mice.
(G) Viability of isolated control (Glut1fl/+) and
LckCreGlut1fl/fl T cells over time in culture with or
without IL-7.
Mean cell count ± SD or representative data from
(C and D) seven and (E and F) five animals and
(A, B, and G) two or more independent experi-
ments are shown.
Cell Metabolism
Glut1 Is Required Selectively in CD4 T Cellssurface expression was measurable within 4 hr of stimulation
and maximal after 24 hr (Figure 1C). Consistent with previous
data implicating the phosphatidylinositol 3-kinase (PI3K)-Akt-
mTORC1 pathway in the regulation of Glut1 expression and traf-
ficking (Frauwirth et al., 2002; Wieman et al., 2007), inhibitors
of PI3K (LY294002), PI3K/mTOR kinase (PP242), or mTORC1
(rapamycin) suppressed the induction of cell-surface Glut1 (Fig-
ure 1D). Glut1 upregulation and cell-surface trafficking is, there-
fore, an early event in T cell activation, mediated in part through
PI3K-Akt-mTORC1 signaling.
Glut1Supports ThymicDevelopment but IsNot Required
for Resting Peripheral T Cell Survival
Based on the dynamic expression of Glut1, the specific role of
this transporter was tested in T cell development and activation.
Glut1fl/fl mice (Young et al., 2011) were crossed with LckCre
transgenicmice to specifically delete Glut1 in early double-nega-
tive (DN) thymocytes. Total thymocyte numbers were reduced
60%–70% in LckCreGlut1fl/fl mice compared to control animalsCell Metabolism 20,(Figure S1A, available online). This
reflected a sharp loss of CD4 CD8 dou-
ble-positive (DP) and CD4 single-posi-
tive (SP) cells, while DN cell numbers
were unchanged and represented an
increased fraction of thymocytes (Figures
S1B and S1C). Within the DN population,
LckCreGlut1fl/flmice had normal numbers
of DN1, DN2, and DN3 and a trend
toward reduced DN4 cells (Figure S1C).
Glut1 therefore contributes to, but is
not required for, thymocyte differentia-
tion. Importantly, the DN3-DN4 stages
at which Glut1-deficient cells began toshow defects corresponds to the highest surface Glut1 expres-
sion (Figure S1D) and most proliferative phase of thymopoiesis
(Shortman et al., 1990).
Persistent SP thymocytes and peripheral T cells may have
failed to delete or may not require Glut1 for development or
survival. To bypass potential developmental defects, Glut1fl/fl
mice were crossed to CD4Cre transgenic mice, which delete
loxP-flanked genes in the DP-to-SP transition following the pro-
liferative DN3-DN4 stage in thymopoiesis. Thymocyte numbers
and phenotype were normal in CD4CreGlut1fl/fl mice (Figures
S2A and S2B). Importantly, peripheral T cells present in both
LckCreGlut1fl/fl and CD4CreGlut1fl/fl mice had efficiently deleted
Glut1 as measured by mRNA and protein (Figures 2A and 2B).
The numbers of lymph node T cells in LckCreGlut1fl/fl mice,
however, were reduced (Figures 2C and 2D). In contrast,
peripheral T cell numbers in CD4CreGlut1fl/fl mice trended
toward a modest reduction, with the only significant difference
being fewer Glut1-deficient CD8 T cells in the spleen (Figures
2E and 2F).61–72, July 1, 2014 ª2014 Elsevier Inc. 63
Figure 3. Glut1 Is Necessary to Support
Activation-Induced Growth, Proliferation,
and Survival
(A and B) Proliferation of CellTrace Violet (CTV)-
labeled control (Glut1fl/fl) and CD4CreGlut1fl/fl (A)
OT-II transgenic T cells on day 3 after adoptive
transfer into intact recipients with or without
immunization with ovalbumin or (B) T cells 6 days
after adoptive transfer into irradiated recipients
for homeostatic proliferation.
(C) Control (Glut1fl/fl) and LckCreGlut1fl/fl T cells
were rested in IL-7 or CD3/CD28 stimulated,
and cell size (forward scatter) of viable cells was
determined by flow cytometry after 24 hr.
(D and E) Control (Glut1fl/+) and LckCreGlut1fl/fl
T cells were CFSE labeled and either rested in IL-7
or CD3/CD28 stimulated and examined by flow
cytometry for (D) proliferation at 72 hr or (E) viability
over time.
(F) Control (Glut1fl/fl) and CD4CreGlut1fl/fl T cells
were CD3/CD28 stimulated 16 hr and analyzed
by immunoblot.
(G) Control (Glut1fl/fl) and CD4CreGlut1fl/fl T cells
were rested in IL-7 or CD3/CD28 stimulated for
10 hr and analyzed by intracellular flow cytometry
and immunoblot.
Data are representative of n = 3mice/group (A and
B), and a minimum of (F and G) two or (C–E) three
experiments were performed. Mean ± SD of three
independent experiments is shown in (E).
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Glut1 Is Required Selectively in CD4 T CellsThe dependence of peripheral T cells on Glut1 for survival was
directly tested bymeasuring cell death in cultures of resting con-
trol or LckCreGlut1fl/fl T cells with or without the addition of inter-
leukin-7 (IL-7) (Figure 2G). IL-7 plays a key role to determine the
survival and basal rates of glucose metabolism of resting T cells
(Carrette and Surh, 2012; Jacobs et al., 2010; Rathmell et al.,
2001). Both control and Glut1-deficient T cells underwent
apoptosis at the same rate in the absence of IL-7. Treatment
with IL-7 protected resting control T cells from death. Glut1-defi-
cient T cells had moderately lower survival than control cells
when cultured with IL-7 but, nonetheless, were also largely pro-
tected from apoptosis. Resting peripheral T cells thus do not
require Glut1 for survival.
Glut1 Is Required for Growth and Proliferation of Mature
T Cells
The decreased numbers of LckCreGlut1fl/fl thymocytes after the
proliferative DN3-DN4 phase and apparent Glut1 independence
of resting T cell survival suggested that Glut1 is selectively
required to support proliferation. To test the dependence of
peripheral T cells on Glut1 for activation-induced proliferation,
ovalbumin (Ova)-specific OT-II T cell receptor (TCR) transgenic64 Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc.control or CD4CreGlut1fl/fl CD4 T cells
were labeled with the proliferation dye
CellTrace Violet and adoptively trans-
ferred into Thy1.1 hosts that were then
immunized with Ova. Importantly, Glut1-
deficient CD4 T cells had reduced prolif-
eration (Figure 3A). We also tested the
ability of Glut1-deficient T cells to un-dergo homeostatic proliferation after adoptive transfer into irra-
diated and lymphopenic recipients. Consistent with a need for
Glut1 to allow proliferation in vivo, Glut1-deficient CD8 and
CD4 T cells underwent only limited homeostatic proliferation
(Figure 3B).
T cells were stimulated in vitro to examine mechanisms that
suppressed proliferation and accumulation of Glut1-deficient
T cells in vivo. Importantly, in vitro-stimulated Glut1-deficient
T cells grew very poorly, as evidenced by a failure to increase for-
ward light scatter by flow cytometry (Figure 3C). Further, activa-
tion sufficient to drive the proliferation of control T cells failed to
induce proliferation (Figure 3D) and instead led to rapid induction
of cell death of many LckCreGlut1fl/fl T cells (Figure 3E). Viable
Glut1-deficient T cells had increased levels of phospho-AMPK
(50 adenosine monophosphate-activated protein kinase) after
activation (Figure 3F), suggesting that these T cells are under
metabolic stress. Further, these cells failed to sustain activated
mTORC1 signaling, as assessed by phosphorylation of the
downstream p70 S6 kinase target, small ribosomal subunit S6
(Figure 3G). The mTOR pathway can broadly regulate nutrient
uptake (McCracken and Edinger, 2013), and the transferrin
receptor (CD71) and the 4F2hc amino acid transporter (CD98)
Figure 4. Glut1 Is Required for Activation-
Induced Metabolic Reprogramming
(A and B) Control (Glut1fl/fl) and LckCreGlut1fl/fl
T cells were rested in IL-7 or CD3/CD28 stimu-
lated, and (A) glucose uptake or (B) glycolytic rate
was measured after 16 hr.
(C–F) Control (Glut1fl/fl) andCD4CreGlut1fl/fl T cells
were rested in IL-7 or CD3/CD28 stimulated for
16 hr. (C) Total lactate produced was measured.
(D) Extracellular acidification rate (ECAR) was
assessed after the addition of glucose (gluc),
oligomycin (oligo), and 2-deoxyglucose (2-DG) at
the indicated times. We determined (E) glycolytic
capacity and (F) the OCR/ECAR ratio.
Mean ± SD (n = 4) is shown from aminimum of two
or more independent experiments.
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Glut1 Is Required Selectively in CD4 T Cellswere not efficiently induced in activated Glut1-deficient T cells
(Figure S3A). Most signaling pathways, however, were un-
changed, as cMyc was induced and phospho-Akt and -ERK
were equivalent or only modestly reduced in activated Glut1-
deficient T cells (Figure S3B). Activation markers were also
induced normally (Figure S3C).
Glucose uptake and glycolysis were measured in resting and
activated T cells to assess themetabolic role of Glut1. Consistent
with a selective role in activation, resting IL-7-treated peripheral
T cells did not rely on Glut1 and had similar rates of glucose
uptake, glycolysis, and lactate production regardless of Glut1
expression (Figures 4A–4C). However, while control T cells
rapidly increased glucosemetabolism after activation, stimulated
LckCreGlut1fl/fl T cells maintained only a basal rate of glucose
uptake and greatly reduced glycolytic rate (Figures 4A and 4B).
Likewise, stimulated CD4CreGlut1fl/fl T cells failed to increase
lactate production when measured directly or by extracellular
acidification rate (ECAR) (Figures 4C and 4D). As a consequence,
activated Glut1-deficient T cells had reduced glycolytic capacity
(Figure 4E) and an elevated ratio of oxygen consumption rate
(OCR) to ECAR (Figure 4F). Glut1 is therefore essential for rapid
metabolic reprogramming to aerobic glycolysis for maximal
growth, survival, and proliferation of in vitro-stimulated T cells.
Activated Human T Cells Require Metabolic
Reprogramming through Glut1
Despite evidence of murine T cell reliance on increased glucose
uptake and glycolysis after stimulation (Frauwirth et al., 2002;
Jacobs et al., 2008; Michalek et al., 2011a; Wang et al., 2011),
metabolic transitions and dependencies in human T cells (hT
cells) are poorly described. To test if a transition from an oxida-
tive to glycolytic metabolism with increased Glut1 was also crit-
ical in human T cell activation, peripheral blood hT cells from
healthy donors were stimulated with anti-CD3 and anti-CD28
for 48 hr. hT cell activation resulted in increased glucose uptake
and glycolytic rate (Figures 5A and 5B). ECAR and OCR alsoCell Metabolism 20,increased, although the ratio of OCR
to ECAR decreased following CD3 and
CD28 stimulation, indicating metabolic
reprogramming toward aerobic glycol-
ysis (Figure 5C). Glut1 was also strongly
upregulated (Figure 5D).To test the dependence of hT cells on Glut1 and glycolytic re-
programming, glucose metabolism was targeted pharmacolog-
ically and genetically. Despite the availability of alternate carbon
sources, glucose-deprived or 2DG-treated hT cells were unable
to grow, upregulate the activation markers CD25 and CD71, or
proliferate (Figures S4A and S4B). The role of Glut1 upregulation
was then tested by transfection of Glut1 or scramble siRNA
pools, and knockdown was validated using semiquantitative
RT-PCR and immunoblot (Figures 5E and S4C). Glut1 siRNA-
transfected hT cells had a significantly lower ability to uptake
glucose and had reduced ECAR after stimulation relative to con-
trol siRNA-transfected cells (Figure 5G). While Glut1 knockdown
did not affect resting hT cell survival, Glut1-deficient hT cells
had a modest, yet significant, reduction in viability when stimu-
lated (Figure S4D). Importantly, Glut1 siRNA-transfected hT cells
also had a reduced ability to grow (Figure 5H) and proliferate
(Figures 5I and 5J) upon stimulation. Thus, activated human
T cells require Glut1 upregulation to support metabolic reprog-
ramming for optimal survival, growth, and proliferation.
Glut1 Is Required for the Generation of Teff, but Not
nTreg or iTreg
We and others have previously shown in vitro that murine Teff
cells (Th1, Th2, and Th17) utilize a highly glycolytic metabolism,
while Treg cells are primarily oxidative and use lipids as fuel
(Michalek et al., 2011a; Shi et al., 2011). Likewise, effector CD8
T cells are glycolytic, whereas memory CD8 T cells utilize lipid
oxidation (Gubser et al., 2013; Pearce et al., 2009; van der Windt
et al., 2012). We first tested the role of Glut1 in CD8 T cell activa-
tion and effector differentiation. While CD4CreGlut1fl/fl CD8
T cells had reduced initial proliferation (Figure 6A), differentiation
to effector function and the ability to express and release gran-
zyme B upon stimulation or to express IL-2, tumor necrosis fac-
tor alpha, and interferon gamma (IFNg) were normal (Figures 6B
and S5A). Normal function of CD8 effectors was not due to failure
of Glut1-deletion, as CD4CreGlut1fl/fl CD8 T cells have sharply61–72, July 1, 2014 ª2014 Elsevier Inc. 65
Figure 5. Activation of Human T Cells Triggers Glut1-Dependent Glycolytic Reprogramming
(A–D) Isolated human T cells were rested in IL-7 (naive) or CD3/CD28 stimulated for 48 hr to measure (A) glucose uptake, (B) glycolytic flux, (C) ECAR and OCR,
and (D) Glut1 expression by flow cytometry.
(E–G) T cells transfected with scrambled or Glut1-targeted siRNA pools were cultured in IL-7 (naive) or CD3/CD28 stimulated 48 hr to measure (E) Glut1 by
immunoblot, (F) glucose uptake, and (G) OCR and ECAR.
(H and I) T cells were transfected as above, CFSE labeled, and rested in IL-7 (naive) or CD3/CD28 stimulated for 72 hr in the presence of IL-2. Flow cytometry
measured (H) cell size by forward scatter and (I) proliferation by CFSE dilution.
(J) T cells were transfected with siRNA and stimulated, and bromodeoxyuridine (BrdU) was added for the final 8 hr of culture. BrdU incorporation was assessed by
flow cytometry.
Data show mean ± SD and are representative of (A–I) three to five or (J) two independent experiments.
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Glut1 Is Required Selectively in CD4 T Cellsreduced Glut1 protein (Figure 6C). Rather, CD8 T cells may
utilize alternate glucose transporters or metabolic programs,
as CD4CreGlut1fl/fl CD8 T cells had increased Glut3 and Glut6
expression (Figures 6C and S5B).
Control and Glut1-deficient Teff and Treg were next examined
to test the selective dependence of CD4 subsets on Glut1. Inter-
estingly, while overall peripheral T cell numbers and frequency
were lower in the spleen of LckCreGlut1fl/fl mice, the CD4+
FoxP3+ natural Treg (nTreg) population was not decreased,
and only FoxP3 negative cells were reduced (Figure 6D). This
selective loss of FoxP3 cells led to a progressive increase in
representation of FoxP3+ nTreg in the peripheral CD4 T cell
compartment (Figure 6E). Naive CD4 T cells can be induced to
differentiate into Th1, Th2, Th17, or Treg subsets in appropriate66 Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc.cytokine conditions (Zhu et al., 2010). CD4 T cells from control
and CD4CreGlut1fl/flmice were therefore activated in vitro under
polarizing conditions to generate Teff and Treg. The addition of
cytokines reduced activation-induced cell death, allowing gen-
eration of each subset. The surviving cells in each case remained
Glut1 deficient (Figure 6F). Importantly, the number of cytokine-
producing cells in each Teff culture and the fraction of viable
cytokine-producing cells in Th1 and Th17 cultures were reduced
by Glut1 deficiency (Figures 6G, S5C, and S5D). The total num-
ber of Teff in each condition was also reduced (Figure S5D).
Conversely, induced Treg cultures were unaffected by Glut1
deletion and maintained normal cell numbers and fraction posi-
tive for FoxP3 as well as the ability to suppress Teff proliferation
(Figures 6G, 6H, S5C, and S5D). The normal number and
Figure 6. Glut1 Is Required for the Generation and Function of Teff, but Not Treg or CTL
(A) CD8 T cells from control (Glut1fl/+) and CD4CreGlut1fl/flmice were CellTrace Violet (CTV)-labeled and rested in IL-7 or CD3/CD28 stimulated with IL-2 for flow
cytometric analysis after 48 hr.
(B and C) Control (Glut1fl/+) and CD4CreGlut1fl/fl cytotoxic CD8 T lymphocytes (CTL) were analyzed (B) after 3 hr restimulation by flow cytometry and (C)
immunoblot.
(D and E) Flow cytometry of control (Glut1fl/fl) and LckCreGlut1fl/fl spleen for FoxP3+CD4 T cells. Shown is the (D) representative plot and (E) cumulative data of the
fraction of CD4 T cells expressing FoxP3.
(F–H) Th1, Th2, Th17, and Treg were induced using control (Glut1fl/+, Glut1fl/fl) and CD4CreGlut1fl/fl CD4 T cells and analyzed by (F) immunoblot and (G) flow
cytometry to determine the number of live-skewed cells expressing indicated subset markers. (H) Treg function was tested in an in vitro suppression assay.
Data are representative of or show mean cell count ± SD from (D and E) five, (F–H) three, or (A–C) two independent experiments.
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Glut1 Is Required Selectively in CD4 T Cellsfunction of Glut1-deficient Treg did not appear due to compen-
sation by alternate glucose transporters, as Gluts 3 and 8 were
unchanged and expressed at low levels, and Glut6 was only
modestly increased by Glut1 deletion (Figure S5E). Rather, these
data suggest that Teff, but not Treg, cells are dependent onGlut1
for expansion and survival.
Glut1 Is Required In Vivo for Expansion of Teff, but Not
Treg, in Inflammatory Disease
The Glut1 dependence of CD4 Teff may allow metabolic target-
ing in immunological disease, and selective Teff dependence on
Glut1 was tested in vivo. Acute GvHD is mediated through TCR
recognition of alloantigen, and the role of glucose relative to lipid
metabolism has been uncertain (Byersdorfer et al., 2013; Gatza
et al., 2011; Saha et al., 2013). We first directly tested if T cells
require Glut1 to induce GvHD by lethal irradiation followed by
transplantation of T cell-depleted bonemarrow alone or together
with total control or CD4CreGlut1fl/fl T cells. Recipients were
monitored over time for weight and survival. In support of a
key role for T cell expression of Glut1 in this setting, alloreactive
Glut1-deficient T cells had a dramatically decreased ability toinduce lethal GvHD (Figures 7A and 7B). Therefore, Glut1 is crit-
ical in T cell induction of GvHD.
Colitis is driven by Th1 and Th17 Teff cells and suppressed
by Treg cells (Brand, 2009). The requirement of Teff for Glut1
to induce inflammatory bowel disease (IBD) was first tested us-
ing an adoptive transfer model (Mottet et al., 2003) in which
sorted naive control andCD4CreGlut1fl/fl T cells were transferred
into immunodeficient Rag1/ recipients. The nonsteroidal anti-
inflammatory drug (NSAID) piroxicam was given 2 weeks after
T cell transfer to induce gut damage and trigger disease. Impor-
tantly,CD4CreGlut1fl/fl T cells were unable to effectively promote
IBD as indicated by weight loss (Figure 7C; day 0 indicates the
start of piroxicam treatment), while control T cells induced signif-
icant weight loss over time. Importantly, both total (Figures 7D
and S6A) and cytokine-producing (Figures S6B and S6C) T cell
numbers were decreased by Glut1 deficiency, and the remaining
T cells lacked Glut1 (Figure S6D).
To test if acute deletion of Glut1 also affected IBD, sorted
naive T cells or nTreg from control or UbiCreERT2Glut1fl/fl mice
were adoptively transferred individually or in combination into
Rag1/ hosts. After 2 weeks to allow homeostatic expansion,Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc. 67
Figure 7. Glut1 Is Selectively Required for
Expansion and Function of Teff, but Not
Treg, in Inflammatory Disease
(A and B) GvHDwas induced with the transplant of
T cell-depleted bone marrow (BM) or BM + control
(Glut1fl/fl orGlut1fl/+) or CD4CreGlut1fl/fl T cells into
allogeneic hosts, and (A) body weight and (B)
survival were measured over time.
(CandD)Naive control (Glut1fl/fl) orCD4CreGlut1fl/fl
T cells were transferred into Rag1/ hosts, and
colitis was triggered 2 weeks later via piroxicam
(Pirox; day 0 on start of Pirox) exposure; (C) animal
weights were measured over time or (D) mice were
sacrificed at day 30, and the number of CD4 T cells
present in the spleen and mesenteric (mes) lymph
nodes was determined by flow cytometry.
(E–H) Rag1/ mice were injected with control
(CreERGlut1+/+, Glut1fl/fl) or CreERGlut1fl/fl naive
T cells. Colitis was triggered by piroxicam expo-
sure 2 weeks after T cell transfer. Animals were
then treated with tamoxifen to activate Cre. (E)
Hematoxylin and eosin (H&E) histology of proximal
colon from mice that received (i) naive control
T cells, (ii) naive CreERGlut1fl/fl T cells, (iii) naive
control T cells plus control Treg, or (iv) naive
control T cells plus CreERGlut1fl/fl Treg. Bar in-
dicates 100 mm; arrow indicates cryptic abscess
and arrowhead indicates a granuloma. The num-
ber of (F) CD4 or (G) IFNg- or IL-17-producing
T cells in the mesenteric (mes) lymph nodes was
determined after 4 weeks by flow cytometry. (H)
Rag1/ mice were coinjected with wild-type
naive T cells and either control (CreERGlut1+/+,
Glut1fl/fl) or CreERGlut1fl/fl nTreg. Mice were
treated after 2 weeks with piroxicam and tamox-
ifen to trigger IBD and activate Cre, and CD4
T cells were determined after 4 weeks.
Data are representative of (A and B) two or
(C–H) three independent experiments and show
(A and C) mean clinical score ± SEM or (D and
F–H) mean ± SD.
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tamoxifen to activate CreERT2 and delete Glut1 in Teff or Treg
subsets in vivo. Although Glut1 deletion was incomplete (Fig-
ure S7A), UbiCreERT2Glut1fl/fl T cells failed to induce inflamma-
tion, gut hyperplasia, or granuloma, as was observed with
control T cells (Figures 7Ei and 7Eii). Broadly scoring colitis,
including architectural distortion, crypt abscesses, severity
of inflammation, ulceration, and percent of bowel affected,
suggested that mice that received Glut1-deficient T cells
were resistant to severe colitis (Figure S7B). Importantly, total
numbers of Glut1-deficient CD4 T cells in the spleen and
mesenteric lymph nodes were significantly reduced relative to
control T cells 4 weeks after tamoxifen treatment (Figures 7F
and S7C). Glut1 deletion also reduced cytokine production
by CD4 Teff, as fewer IFNg- and IL-17-producing cells were
present in mice receiving Glut1-deficient T cells (Figures 7G,
S7D, and S7E).68 Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc.Importantly, Glut1-deficient Treg ap-
peared functional in vivo and capable
of inhibiting Teff in IBD. Glut1-deficientnTreg suppressed Teff expansion similar to wild-type nTreg, as
total CD4+ cell numbers in the spleen and mesenteric lymph no-
des and gut pathology were identical when control or Glut1-defi-
cient nTreg cells were transferred together with control Teff cells
(Figures 7Eiii, 7Eiv, 7H, and S7F). Thus, while Teff populations
require Glut1 expression to drive inflammatory colitis, in vitro
and in vivo data support a model in which Treg cells appear
capable to suppress Teff-mediated inflammation and expansion
irrespective of Glut1 expression. Dependence of activated
T cells and Teff on Glut1 may therefore allow selective targeting
of T cell glucose metabolism to suppress inflammatory re-
sponses and promote tolerance and immune suppression.
DISCUSSION
The in vivo metabolic demands of T cell activation, proliferation,
and differentiation and the programs that T cells initiate to
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mune response (MacIver et al., 2013). In vivo, T cells require
mitochondrial ROS (Sena et al., 2013), lipid synthesis (Kidani
et al., 2013), and amino acid uptake (Sinclair et al., 2013). The
mechanism and role of glucose uptake in T cell homeostasis,
activation, and differentiation have not been directly tested
in vivo. Here, our approach that directly targeted the first step
of glucose metabolism by genetic deletion of Glut1 identified
a selective reliance on this glucose transporter in T cell prolifer-
ation and CD4 Teff expansion to induce GvHD and colitis, while
Treg appear largely Glut1 independent.
In addition to the cMyc (Wang et al., 2011) and estrogen-
related receptor a (ERRa) (Michalek et al., 2011b) transcription
factors that regulate T cell metabolism, mTOR and the PI3K-
Akt-mTORC1 signaling pathway can promote Glut1 cell-surface
trafficking, glycolysis, and lipid synthesis (Du¨vel et al., 2010;Wie-
man et al., 2007) and Teff (Waickman and Powell, 2012). T cell-
specific deletion of mTOR kinase to eliminate both mTORC1
and mTORC2 prevented generation of Teff but allowed estab-
lishment of functional Treg (Delgoffe et al., 2009). Conversely,
specific deletion of mTORC1 activation or that of its components
has been shown in distinct settings to either not affect (Delgoffe
et al., 2011) or prevent (Zeng et al., 2013) Treg suppressive
function. These data suggest that mTOR-driven glucose or lipid
metabolism may be critical for Treg (Zeng et al., 2013). How-
ever, decreased mTORC1 signaling can lead to exacerbated
mTORC2 activity (Zeng et al., 2013) that can also promote glyco-
lytic metabolism (Gubser et al., 2013; Masui et al., 2013) and
may thus suppress Treg activity. Indeed, simultaneous deletion
of essential mTORC1 and mTORC2 components or mTOR itself
restored Treg function (Delgoffe et al., 2009; Zeng et al.,
2013). This complex interplay between the multiple mTOR-
induced signaling and metabolic events has hindered mecha-
nistic interpretation of the specific role of metabolic regulation
in T cell function and fate. Our studies directly test the role of
Glut1 upregulation in T cell activation and subsets to show a
selective Glut1 dependence on activated Teff and Glut1 inde-
pendence of Treg.
Glucose uptake is mediated through the 14-member Glut
transporter family; we show that CD4 T cells express Gluts1, 3,
6, and 8. Each was regulated in T cell activation and differentia-
tion, with the highest expression of Glut1 and Glut3. Gluts 6 and
8 were expressed at relatively low levels, and their specific roles
are unclear at this time. The high Glut3 expression and Glut1
independence of resting T cells and CD8 Teff suggests a role
for Glut3-mediated glucose uptake. While CD4 Teff cells were
reliant on Glut1-directed metabolism, functional Treg could be
generated from naive T cells lacking Glut1, despite expressing
only low levels of Glut3. These data are consistent with Treg
use of mitochondrial oxidative pathways rather than glucose
metabolism (Michalek et al., 2011a; Shi et al., 2011). In support
of an alternate metabolic program, Treg can be generated in
the absence of glucose (Michalek et al., 2011a) or in the pres-
ence of 2DG (Shi et al., 2011).
Despite expression of multiple glucose transporters, our data
demonstrate a specific requirement for Glut1 in both activated
mouse and human T cells in vitro and in vivo. The Glut1-depen-
dent molecular switch to elevate glycolysis was critical for rapid
human T cell growth and proliferation, as Glut1 knockdownsuppressed glycolysis and slowed the transition of human
T cells from quiescence to proliferation. Likewise, activation
of murine cells led to a dependence on Glut1 to support cell
growth, proliferation, and prevention of apoptosis. Thymocytes
in the proliferative DN3-DN4 transition expressed Glut1 at a
high level and were also sensitive to Glut1 deficiency. In the
absence of Glut1, activated mature T cells failed to increase
glucose uptake and glycolysis beyond resting levels and had
selectively reduced growth and proliferation, and many cells
underwent apoptosis. These broad inhibitory effects of Glut1
deficiency were potentially due to AMPK activation and sup-
pression of mTORC1 in vitro and in vivo, which resulted in fewer
inflammatory cytokine-producing cells (Delgoffe et al., 2011;
MacIver et al., 2011).
The differential requirements of specific T cell populations for
Glut1 may reflect specific functional needs for a highly glycolytic
metabolism. Aerobic glycolysis is closely linked with cell growth
to generate increased mass for cell proliferation (Vander Heiden
et al., 2009), and Glut1-deficient T cells failed to grow after
stimulation. Proliferation was also suppressed, and cell death
increased, possibly as a consequence of inadequate nutrients
to support biosynthesis and prevent AMPK suppression of
mTORC1. In addition, Glut1-deficient CD4 Teff cells also had
reduced production of IFNg. Glucose deprivation has been
shown to lead to a specific reduction of IFNg production
in vitro (Cham and Gajewski, 2005; Jacobs et al., 2008), and
glycolytic flux has been implicated in IFNg translation (Chang
et al., 2013). Indeed, we found both reduced cell numbers and
decreased inflammatory cytokine production by Glut1-deficient
Th1 and Th17. In contrast to Teff, our data show that Treg cells
appear to utilize an alternate metabolic program. It remains to
be determined, however, if Treg cells induce aerobic glycolysis
using an alternate glucose transporter or if they proliferate
using a distinct metabolic program. The metabolic requirements
of different T cell activation states and subsets may also play
a broad role in immune homeostasis or disease, supporting
specific T cell populations in distinct tissues and immunologic
settings. Together, our data demonstrate a primary role for
Glut1 to support Teff expansion and survival.
Identifying biochemical requirements for T cell activation and
the generation of effector and regulatory T cells has been a
long-sought goal in efforts to treat inflammatory diseases.Mech-
anisms that control cell metabolism to support the specific func-
tional needs of these cells have been described only recently
(MacIver et al., 2013) but have proven promising (Bian et al.,
2009; Eleftheriadis et al., 2013; Ostroukhova et al., 2012; Shi
et al., 2011). To date, pharmacologic approaches have pro-
vided limited mechanistic insight, and the role of glucose uptake
has been uncertain. Data presented here demonstrate that
despite expression of multiple Glut family transporters, Glut1 is
specifically required for the cell-intrinsic metabolic program of
activated T cells and CD4 Teff in vitro and in vivo to drive inflam-
mation in both colitis and GvHD. These data show that despite
a potential requirement for lipid oxidation (Byersdorfer et al.,
2013; Gatza et al., 2011), Glut1 is central in the metabolism of
Teff and in GvHD. Glut1, however, is not required in all settings,
as resting T cells, CD8 Teff, and Treg were capable of Glut1-in-
dependent function. Collectively, these findings demonstrate
that distinct T cell subsets utilize selective metabolic programsCell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc. 69
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regulations of specific nutrient transporters in T cell activation
and subsets may now provide opportunities to exploit metabolic
distinctions of cells in the immune system to control inflamma-
tory diseases.
EXPERIMENTAL PROCEDURES
Human T Cell Isolation, siRNA, Stimulation, and Culture
Human T cells were isolated bymagnetic bead negative selection and cultured
under standard conditions. Where indicated, cells were supplemented with
10 mM 2DG or cultured in glucose-free media and supplemented as indicated
with D-glucose. Human siRNA pools were transiently transfected by nucleo-
fection (Amaxa), and cells rested 4–6 hr before stimulation. Where indicated,
cells were activated on plates coated with anti-CD3 and anti-CD28, stimulated
in the presence of 20 ng/ml IL-2, or rested in 10 ng/ml IL-7. Human samples
were obtained under Institutional Review Board approved protocols.
Mice
Mice were obtained from the Jackson Laboratory or described previously
(Young et al., 2011). All procedures were performed under protocols approved
by the Duke University Medical Center Institutional Animal Care and Use
Committee (IACUC).
Murine T Cell Isolation, Stimulation, and Culture
Murine total, CD8, or CD4 T cells were isolated by magnetic bead negative
selection and cultured under standard conditions. Where stated, cells were
cultured in 10 ng/ml IL-7, activated by stimulation on plates coated with
anti-CD3 and anti-CD28, or stimulated in the presence of 10 mM LY294002,
20 nM rapamycin, or 1 mM PP242.
Metabolic Assays
Glycolysis and glucose uptake assays were normalized to cell number and
have been described previously (Wieman et al., 2007). OCR and ECAR were
measured with an XF24 extracellular flux analyzer (Seahorse Bioscience) using
manufacturer-recommended protocols. For certain experiments, ECAR was
measured over time following injection of 10 mM D-glucose, 1 mM oligomycin,
and 20 mM 2DG. Lactate production was measured by colorimetric assay
(Abcam).
Flow Cytometry, Proliferation, and Viability Measurements
Intracellular cytokines were measured as described (Michalek et al., 2011a).
To measure transcription factors, granzyme B, and phospho-S6, cells were
fixed in paraformaldehyde, methanol permeabilized, and then labeled with
fluorophore-conjugated antibodies. Cell proliferation was assayed by flow
cytometry of carboxyfluorescein succinimidyl ester (CFSE)- or CellTrace Violet
(CTV)-labeled cells, and viability was determined by propidium iodide exclu-
sion (PI; Invitrogen). To assay bromodeoxyuridine (BrdU) incorporation, cells
were cultured with BrdU for 8 hr, ethanol fixed, and then stained with Alexa
Fluor 647 anti-BrdU (Invitrogen). Cells were labeled with PI for cell-cycle anal-
ysis and analyzed as described (Darzynkiewicz and Juan, 2001).
T Cell Differentiation and Treg Suppressor Assay
Naive CD4+CD25 T cells were used to generate subsets as described (Micha-
lek et al., 2011a). To generate CD8+ cytotoxic T lymphocytes (CTL), CD8+
T cells were stimulated for 48 hr with anti-CD3 and anti-CD28 in the presence
of 20 ng/ml IL-2. Cells were then cultured with 20 ng/ml IL-2 alone for a further
72 hr. Treg suppression was measured as described (Michalek et al., 2011a).
Glucose Transporter Family Expression
RNA was isolated using a RNeasy Plus Mini Kit (QIAGEN). Glut family abso-
lute copy number was determined as described (Rudolph et al., 2011). Ct
values were fitted to regression curves to quantify transcript copy number.
RNA was reverse transcribed using a commercially available kit for semiquan-
titative real-time PCR performed using a fluorescent dsDNA dye, and mRNA
levels were normalized to 18S RNA or b2 microglobin mRNA using the DDCt
method.70 Cell Metabolism 20, 61–72, July 1, 2014 ª2014 Elsevier Inc.Immunoblotting
Immunoblotting was performed using standard techniques as described pre-
viously (Jacobs et al., 2008).
Homeostatic Proliferation
Total T cells were isolated from control and CD4CreGlut1fl/fl mice, labeled
with CTV, and adoptively transferred into irradiated Thy1.1 hosts (600cGy).
At 6 days after transfer, lymphocytes were isolated and proliferation was
assessed by CTV dilution of Thy1.2-labeled cells.
Ova Immunization
Ova-specific OT-II T cell receptor (TCR) Thy1.2 transgenic control
(CD4CreGlut+/+) or knockout (CD4CreGlut1fl/fl) CD4 T cells were labeled
with CTV and adoptively transferred into wild-type Thy1.1 hosts. After 1 day,
mice were immunized with intraperitoneal (i.p.) Ova in Complete Adjuvant
(Sigma). After 3 days, lymphocyte proliferation was assessed by CTV dilution
of Thy1.2-labeled cells.
Graft versus Host Disease
Lethally irradiated (8.5Gy)BALB/cmicewere injected intravenouslywith13107
T cell-depleted bone marrow (TCD BM) cells along with 13 106 purified T cells
from allogeneic donors. Body weight, survival, and clinical evidence of GvHD,
such as skin changes, diarrhea, hunched posture, and activity, were closely
monitored after transplantation as described previously (Chen et al., 2003).
Colitis
Sorted naive effector T cells (CD4+CD25CD45RBhi) were i.p. injected into
C57BL/6 RAG1/ recipients. Sorted Treg (CD4+CD25+CD45RBlo) cells
were coinjected as indicated. Because the mice were free of enteric patho-
gens, includingHelicobacter species, and colitis may not occur spontaneously
in this setting, mice were fed 200 ppm piroxicam in powdered rodent chow for
5 days 2 weeks after T cell injection to increase gut permeability and trigger
colitis (Hale et al., 2005). Mice were then i.p. injected with 4 mg/kg/day of
tamoxifen where indicated for 4 days to induce Glut1fl deletion and monitored
three times weekly. Colon tissue was isolated for pathology analysis and dis-
ease scoring as described (Hale et al., 2005).
Statistical Analysis
Statistical analyses were performed with Prism software (GraphPad) using the
nonparametric Mann-Whitney test. The Wilcoxon signed-rank test was used
for paired samples. Longitudinal data were analyzed by two-way ANOVA
followed by Tukey’s test. Statistically significant results are indicated (*p <
0.05), and n.s. indicates select nonsignificant data. Error bars show mean ±
SD unless otherwise indicated to show mean ± SEM.
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